The agency added only companies involved with processing, including Dosecann LD, which was licensed on December 21st, as well as ARA – Avanti Rx Analytics, Hollyweed Manufacturing & Extracts, SynFine Research Limited, Toronto Research Chemicals and Zenalytic Laboratories, which were all added on the 24th. These were the first processing-only licenses awarded since Medipharm Labs (TSXV: LABS) (OTC: MLCPF) received its license in late March, the first time an LP had received a processing license without also receiving a cultivation license.
ARA – Avanti RX is owned by Aphria (TSX: APHA (NYSE: APHA), which acquired it in the Nuuvera acquisition. Dosecann is a wholly owned subsidiary of Auxly Cannabis Group (TSXV: XLY) (OTC: CBWTF). Zenalytics Labaoratories is wholly owned by GTEC Holdings (TSXV: GTEC) (OTC: GGTTF).
In 2018, Health Canada added a total of 56 LPs after adding 47 in 2017.
Based in Houston, Alan leverages his experience as founder of online community 420 Investor, the first and still largest due diligence platform focused on the publicly-traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. At New Cannabis Ventures, he is responsible for content development and strategic alliances. Before shifting his focus to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst following over two decades in research and portfolio management. A prolific writer, with over 650 articles published since 2007 at Seeking Alpha, where he has 70,000 followers, Alan is a frequent speaker at industry conferences and a frequent source to the media, including the NY Times, the Wall Street Journal, Fox Business, and Bloomberg TV. Contact Alan: Twitter | Facebook | LinkedIn | Email
